Avid Bioservices Shares Gain Following Higher Revenue, Positive Outlook

Dow Jones

Sep 11, 2024

By Connor Hart

Shares of Avid Bioservices jumped after the company posted higher revenue in its fiscal first quarter and forecast continued growth.

The stock was up 19% to $10.61 on Tuesday, on pace for its largest percent increase since March 14, 2023. Shares are up 63% since the beginning of the year.

The Tustin, Calif., biopharmaceutical company on Monday reported a net loss of $5.5 million, or 9 cents a share, in the quarter ended July 31, compared with a loss of $2.1 million, or 3 cents a share, in last year's quarter.

Revenue rose 6% to $40.2 million, boosted by an increase in process development revenue. Analysts polled by FactSet expected revenue of $40.8 million.

Avid signed $66 million of net new orders during the recent quarter, resulting in a backlog of $219 million, up 13% from last year. The company said it anticipates a significant amount of its backlog will be recognized as revenue over the next five fiscal quarters.

Chief Executive Nick Green said the company will generate higher margins as revenue, as well as capacity utilization, increases.

The company backed its full-year revenue outlook, and expects sales between $160 million and $168 million, the midpoint of which is just above the $163.7 million that analysts polled by FactSet expect.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 10, 2024 15:14 ET (19:14 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2466498530"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466498530\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2466498530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-11 03:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466498530","market":"other","top_or_hot":-1,"title":"Avid Bioservices Shares Gain Following Higher Revenue, Positive Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Avid Bioservices jumped after the company posted higher revenue in its fiscal first quarter and forecast continued growth. \n</p>\n<p>\n  The stock was up 19% to $10.61 on Tuesday, on pace for its largest percent increase since March 14, 2023. Shares are up 63% since the beginning of the year. \n</p>\n<p>\n  The Tustin, Calif., biopharmaceutical company on Monday reported a net loss of $5.5 million, or 9 cents a share, in the quarter ended July 31, compared with a loss of $2.1 million, or 3 cents a share, in last year's quarter. \n</p>\n<p>\n  Revenue rose 6% to $40.2 million, boosted by an increase in process development revenue. Analysts polled by FactSet expected revenue of $40.8 million. \n</p>\n<p>\n  Avid signed $66 million of net new orders during the recent quarter, resulting in a backlog of $219 million, up 13% from last year. The company said it anticipates a significant amount of its backlog will be recognized as revenue over the next five fiscal quarters. \n</p>\n<p>\n  Chief Executive Nick Green said the company will generate higher margins as revenue, as well as capacity utilization, increases. \n</p>\n<p>\n  The company backed its full-year revenue outlook, and expects sales between $160 million and $168 million, the midpoint of which is just above the $163.7 million that analysts polled by FactSet expect. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 10, 2024 15:14 ET (19:14 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avid Bioservices Shares Gain Following Higher Revenue, Positive Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvid Bioservices Shares Gain Following Higher Revenue, Positive Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-09-11 03:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Avid Bioservices jumped after the company posted higher revenue in its fiscal first quarter and forecast continued growth. \n</p>\n<p>\n  The stock was up 19% to $10.61 on Tuesday, on pace for its largest percent increase since March 14, 2023. Shares are up 63% since the beginning of the year. \n</p>\n<p>\n  The Tustin, Calif., biopharmaceutical company on Monday reported a net loss of $5.5 million, or 9 cents a share, in the quarter ended July 31, compared with a loss of $2.1 million, or 3 cents a share, in last year's quarter. \n</p>\n<p>\n  Revenue rose 6% to $40.2 million, boosted by an increase in process development revenue. Analysts polled by FactSet expected revenue of $40.8 million. \n</p>\n<p>\n  Avid signed $66 million of net new orders during the recent quarter, resulting in a backlog of $219 million, up 13% from last year. The company said it anticipates a significant amount of its backlog will be recognized as revenue over the next five fiscal quarters. \n</p>\n<p>\n  Chief Executive Nick Green said the company will generate higher margins as revenue, as well as capacity utilization, increases. \n</p>\n<p>\n  The company backed its full-year revenue outlook, and expects sales between $160 million and $168 million, the midpoint of which is just above the $163.7 million that analysts polled by FactSet expect. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 10, 2024 15:14 ET (19:14 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDMO","symbol_name":"Avid Bioservices, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2466498530","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466498530","pubTimestamp":1725995640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Avid Bioservices jumped after the company posted higher revenue in its fiscal first quarter and forecast continued growth.The stock was up 19% to $10.61 on Tuesday, on pace for its largest percent increase since March 14, 2023. Shares are up 63% since the beginning of the year.The Tustin, Calif., biopharmaceutical company on Monday reported a net loss of $5.5 million, or 9 cents a share, in the quarter ended July 31, compared with a loss of $2.1 million, or 3 cents a share, in last year's quarter.Revenue rose 6% to $40.2 million, boosted by an increase in process development revenue. Analysts polled by FactSet expected revenue of $40.8 million.Avid signed $66 million of net new orders during the recent quarter, resulting in a backlog of $219 million, up 13% from last year. The company said it anticipates a significant amount of its backlog will be recognized as revenue over the next five fiscal quarters.Chief Executive Nick Green said the company will generate higher margins ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CDMO":"Avid Bioservices, Inc.","CDMOP":"Avid Bioservices, Inc. 10.50% Series E Convertible Preferred"},"translate_title":"Avid Bioservices股价因收入增加和前景乐观而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMO":0.9,"CDMOP":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Avid Bioservices jumped after the company posted higher revenue in its fiscal first quarter and forecast continued growth. \n\n\n  The stock was up 19% to $10.61 on Tuesday, on pace for its largest percent increase since March 14, 2023. Shares are up 63% since the beginning of the year. \n\n\n  The Tustin, Calif., biopharmaceutical company on Monday reported a net loss of $5.5 million, or 9 cents a share, in the quarter ended July 31, compared with a loss of $2.1 million, or 3 cents a share, in last year's quarter. \n\n\n  Revenue rose 6% to $40.2 million, boosted by an increase in process development revenue. Analysts polled by FactSet expected revenue of $40.8 million. \n\n\n  Avid signed $66 million of net new orders during the recent quarter, resulting in a backlog of $219 million, up 13% from last year. The company said it anticipates a significant amount of its backlog will be recognized as revenue over the next five fiscal quarters. \n\n\n  Chief Executive Nick Green said the company will generate higher margins as revenue, as well as capacity utilization, increases. \n\n\n  The company backed its full-year revenue outlook, and expects sales between $160 million and $168 million, the midpoint of which is just above the $163.7 million that analysts polled by FactSet expect. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 10, 2024 15:14 ET (19:14 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}